scholarly journals Antibodies to Human Herpesvirus 8 in POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, Skin Changes) Syndrome with Multicentric Castleman's Disease

1999 ◽  
Vol 28 (3) ◽  
pp. 678-679 ◽  
Author(s):  
Laurent Bélec ◽  
François‐Jérôme Authier ◽  
Ali Si Mohamed ◽  
Martin Soubrier ◽  
Romain K. Gherardi
Keyword(s):  
Castleman’S Disease ◽  
Human Herpesvirus ◽  
M Protein ◽  
Human Herpesvirus 8 ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Skin Changes ◽  
Herpesvirus 8 ◽  
Multicentric Castleman's Disease

scholarly journals Human Herpesvirus-8 Infection Associated with Kaposi Sarcoma, Multicentric Castleman's Disease, and Plasmablastic Microlymphoma in a Man with AIDS: A Case Report with Review of Pathophysiologic Processes

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Christian Eaton ◽  
Russell Dorer ◽  
David M. Aboulafia
Keyword(s):  
Lymph Node ◽  
Highly Active Antiretroviral Therapy ◽  
Castleman’S Disease ◽  
Human Herpesvirus ◽  
Kaposi Sarcoma ◽  
Human Herpesvirus 8 ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Herpesvirus 8 ◽  
Multicentric Castleman's Disease

Kaposi sarcoma (KS), multicentric Castleman's disease (MCD), and plasmablastic microlymphoma, are all linked to human herpesvirus-8 (HHV-8) infection and HIV-induced immunodeficiency. Herein, we describe the case of a Kenyan man diagnosed with HIV in 2000. He deferred highly active antiretroviral therapy (HAART) and remained in good health until his CD4+ count declined in 2006. He was hospitalized with bacterial pneumonia in 2008, after which he agreed to take HAART but did so sporadically. In 2010, he was hospitalized with fever, lymphadenopathy, pancytopenia, and an elevated HHV-8 viral load. A lymph node biopsy showed findings consistent with KS, MCD, and plasmablastic microlymphoma. Eight months after starting liposomal doxorubicin, Rituximab, and a new HAART regimen, he has improved clinically, and his HIV and HHV-8 viral loads are suppressed. These three conditions, found in the same lymph node, underscore the inflammatory and malignant potential of HHV-8, particularly in the milieu of HIV-induced immunodeficiency.

Practical Management of Castleman's Disease

2016 ◽  
Vol 136 (1) ◽  
pp. 16-22
Author(s):  
Musa Fares Alzahrani ◽  
Mansoor Radwi ◽  
Heather A. Leitch
Keyword(s):  
Hiv Infection ◽  
Interleukin 6 ◽  
Lymphoproliferative Disorder ◽  
Treatment Options ◽  
Castleman’S Disease ◽  
Human Herpesvirus ◽  
Human Herpesvirus 8 ◽  
Castleman's Disease ◽  
Herpesvirus 8 ◽  
Hiv Negative

Castleman's disease (CD) is a rare lymphoproliferative disorder that is most commonly present in multicentric (MCD) form in association with HIV infection. Interleukin-6 (IL-6) and human herpesvirus-8 (HHV-8) play major roles in MCD pathogenesis. Important treatment options have recently become available, particularly with the introduction of IL-6 and IL-6 receptor inhibitors for the treatment of HIV-negative patients with MCD. Though advances in therapy may improve outcomes in some patients, the prognosis remains guarded, and a stratified approach to the management of MCD is needed.

Sign in / Sign up

Export Citation Format

Share Document